Suppr超能文献

动脉粥样硬化性心血管疾病背景下的统计生命货币价值。

The Monetary Value of a Statistical Life in the Context of Atherosclerotic Cardiovascular Disease.

作者信息

Martínez-Pérez Jorge-Eduardo, Sánchez-Martínez Fernando-Ignacio, Abellán-Perpiñán José-María, Pascual-Figal Domingo

机构信息

Department of Applied Economics, Faculty of Economics and Business, University of Murcia, Campus de Espinardo, Edificio no. 2, 30100, Murcia, Spain.

Hospital Virgen de la Arrixaca, Centro Nacional de Investigaciones Cardiovasculares (CNIC), University of Murcia, Murcia, Spain.

出版信息

Pharmacoeconomics. 2025 Jun;43(6):677-689. doi: 10.1007/s40273-025-01482-3. Epub 2025 Mar 29.

Abstract

AIM

This study aims to estimate the value of a statistical life (VSL) in the context of atherosclerotic cardiovascular disease (ASCVD) in Spain using a contingent valuation/standard gamble (CV/SG) chained approach.

METHODS

The study employed a two-stage preference elicitation method that combined contingent valuation and a modified standard gamble technique. Specifically, willingness-to-pay and willingness-to-accept values were obtained for two health states depicting hypothetical outcomes following cardiovascular events. Subsequently, relative utility losses for the health states were derived using a modified standard gamble framing two risky choices. Chaining these elicited values allowed for VSL calculation without requiring direct valuation of small mortality risk reductions. The study was conducted through in-person interviews with a representative sample of 412 Spanish adults selected by stratified quotas.

RESULTS

The estimated VSL range is from 1.59 to 2.06 million euros. Minor differences emerge between VSL figures on the basis of each of the two health states. These VSL estimates for ASCVD are congruent with the recent update of the official VSL estimated for Spain in the context of road traffic accidents, though the upper limit of the range is slightly higher (almost 9%).

CONCLUSIONS

VSL estimates align with existing ranges in other European countries, particularly in the context of road safety, where a significant portion of existing studies is concentrated. Comparisons with other contexts, involving cardiovascular diseases, also lend support to the estimates presented here.

摘要

目的

本研究旨在采用条件估值/标准博弈(CV/SG)链式方法,估计西班牙动脉粥样硬化性心血管疾病(ASCVD)背景下的统计生命价值(VSL)。

方法

该研究采用了两阶段偏好诱导方法,将条件估值与改良的标准博弈技术相结合。具体而言,针对描述心血管事件后假设结果的两种健康状态,获取了支付意愿和接受意愿值。随后,使用构建两个风险选择的改良标准博弈得出这些健康状态的相对效用损失。将这些得出的值进行链接,无需对小幅度死亡风险降低进行直接估值即可计算VSL。该研究通过对412名西班牙成年人的代表性样本进行分层配额抽样并进行面对面访谈来开展。

结果

估计的VSL范围为159万至206万欧元。基于两种健康状态各自得出的VSL数字之间存在细微差异。这些ASCVD的VSL估计值与西班牙在道路交通事故背景下官方VSL的最新估计值一致,尽管该范围的上限略高(近9%)。

结论

VSL估计值与其他欧洲国家的现有范围一致,特别是在道路安全方面,现有研究的很大一部分集中于此。与涉及心血管疾病的其他背景进行比较,也支持此处给出的估计值。

相似文献

1
The Monetary Value of a Statistical Life in the Context of Atherosclerotic Cardiovascular Disease.
Pharmacoeconomics. 2025 Jun;43(6):677-689. doi: 10.1007/s40273-025-01482-3. Epub 2025 Mar 29.
2
[Monetary value of the human costs of road traffic injuries in Spain].
Gac Sanit. 2015 Sep;29 Suppl 1:76-8. doi: 10.1016/j.gaceta.2015.02.001. Epub 2015 Sep 2.
4
Willingness to pay for mortality risk reduction for traffic accidents in Myanmar.
Accid Anal Prev. 2018 Sep;118:18-28. doi: 10.1016/j.aap.2018.05.018. Epub 2018 May 30.
5
How Much Is a Human Life Worth? A Systematic Review.
Value Health. 2021 Oct;24(10):1531-1541. doi: 10.1016/j.jval.2021.04.003. Epub 2021 May 25.
7
Systematic Review to Update 'Value of a Statistical Life' Estimates for Australia.
Int J Environ Res Public Health. 2021 Jun 7;18(11):6168. doi: 10.3390/ijerph18116168.
8
Value of a QALY and VSI estimated with the chained approach.
Eur J Health Econ. 2019 Sep;20(7):1063-1077. doi: 10.1007/s10198-019-01077-8. Epub 2019 Jun 6.
9
Dread and Risk Elimination Premium for the Value of a Statistical Life.
Risk Anal. 2019 Nov;39(11):2391-2407. doi: 10.1111/risa.13341. Epub 2019 Jun 13.
10
The value of a statistical life in the context of road safety: a new value transfer approach.
Traffic Inj Prev. 2025 Apr 22:1-8. doi: 10.1080/15389588.2025.2476607.

本文引用的文献

1
Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach.
Pharmacoeconomics. 2025 Jan;43(1):109-122. doi: 10.1007/s40273-024-01441-4. Epub 2024 Oct 25.
2
A Feasible Estimation of a "Corrected" EQ-5D Social Tariff.
Value Health. 2024 Sep;27(9):1243-1250. doi: 10.1016/j.jval.2024.05.004. Epub 2024 May 23.
3
Global Trends in Atherosclerotic Cardiovascular Disease.
Clin Ther. 2023 Nov;45(11):1087-1091. doi: 10.1016/j.clinthera.2023.09.020. Epub 2023 Oct 30.
5
A systematic review of SF-6D health state valuation studies.
J Med Econ. 2023 Jan-Dec;26(1):584-593. doi: 10.1080/13696998.2023.2195753.
6
The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health.
J Am Coll Cardiol. 2022 Dec 20;80(25):2361-2371. doi: 10.1016/j.jacc.2022.11.005. Epub 2022 Nov 9.
7
8
How Much Is a Human Life Worth? A Systematic Review.
Value Health. 2021 Oct;24(10):1531-1541. doi: 10.1016/j.jval.2021.04.003. Epub 2021 May 25.
9
The societal monetary value of a QALY associated with EQ-5D-3L health gains.
Eur J Health Econ. 2020 Apr;21(3):363-379. doi: 10.1007/s10198-019-01140-4. Epub 2019 Nov 28.
10
Value of a QALY and VSI estimated with the chained approach.
Eur J Health Econ. 2019 Sep;20(7):1063-1077. doi: 10.1007/s10198-019-01077-8. Epub 2019 Jun 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验